CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.

导出 LinkOut

翻译打印收藏纠错

作者： Tobias,Bexte ^[1] ; Jamal,Alzubi ^[2] ; Lisa Marie,Reindl ^[3] ; Philipp,Wendel ^[4] ; Ralf,Schubert ^[5] ; Emilia,Salzmann-Manrique ^[1] ; Ivana,von Metzler ^[2] ; Toni,Cathomen ^[1] ; Evelyn,Ullrich ^[2]

作者单位： Childrens' Hospital, Experimental Immunology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany. ^[1] Frankfurt Cancer Institute, Goethe University, Frankfurt am Main, Germany. ^[2] University Cancer Center (UCT) Frankfurt-Marburg, Frankfurt am Main, Germany. ^[3] Institute for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg, Freiburg, Germany. ^[4] Center for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ^[5] Childrens' Hospital, Division for Allergy, Pneumology and Cystic Fibrosis, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany. ^[6] Childrens' Hospital, Department for Pediatric Stem Cell Transplantation and Immunology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany. ^[7] Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany. ^[8] German Cancer Consortium (DKTK) partner site Frankfurt/Mainz, Frankfurt am Main, Germany. ^[9]

关键词 CRISPR-Cas Genome editing HLA-E KLRC1 NK cells NKG2A immunotherapy inhibitory receptors multiple myeloma

主题词人类(Humans);杀伤细胞, 天然(Killer Cells, Natural);多发性骨髓瘤(Multiple Myeloma);NK细胞凝集素样受体亚家族C(NK Cell Lectin-Like Receptor Subfamily C)

DOI 10.1080/2162402X.2022.2081415

PMID 35694192

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交